Related Experiment Video
Updated: Jun 15, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Cenobamate-associated weight loss (Cenobaweight study)
Jafar Hashem1,2, Swetha Ade3, Shir Ivanier1
1Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Cenobamate (CNB) use in epilepsy patients is linked to significant unintentional weight loss in a notable number of individuals. Dose reduction may reverse this effect without worsening seizures.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Limited data exists on weight changes associated with Cenobamate (CNB).
- Concerns regarding clinically significant weight loss prompted this case-control study.
Purpose of the Study:
- To evaluate weight changes in patients with epilepsy treated with Cenobamate.
- To assess the incidence and potential reversibility of weight loss associated with CNB.
Main Methods:
- A case-control study evaluated 118 epilepsy patients with at least 180 days of CNB exposure.
- Baseline weight, trough, and peak weights during CNB treatment were recorded.
- Concomitant antiseizure medications (ASMs) were also documented.
Main Results:
- 27.8% of patients experienced at least 10% weight loss; 5.1% had ≥20% weight loss.
- Higher CNB doses (≥200 mg/d) were associated with greater weight loss.
- Weight loss effects appeared reversible with dose reduction in some patients, without seizure exacerbation.
Conclusions:
- A significant number of patients experienced unintentional weight loss with CNB use.
- Weight loss may be reversible with CNB dose reduction.
- Systematic weight monitoring is recommended for all patients on CNB, with consideration for dose adjustment if excessive weight loss occurs.
More Related Videos
08:44Electrocorticographic Recording of Cerebral Cortex Areas Manipulated Using an Adeno-Associated Virus Targeting Cofilin in Mice
Published on: February 21, 2021
13:09Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet
Published on: July 31, 2021
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Drugs for Treatment of Constipation-Predominant IBS
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Bulimia Nervosa
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists